Vasopressin antagonists: Pharmacotherapy for the treatment of heart failure

Annals of Pharmacotherapy

Volumn 44, Issue 4, 2010, Pages 680-687

  Reilly, Timothy ^a,b   Schork, Michelle R ^c  

^a RUTGERS UNIVERSITY   (United States)

^b University Medical Center at Princeton   (United States)

^c MONMOUTH MEDICAL CENTER   (United States)

Author keywords

Conivaptan; Heart failure; Hyponatremia; Lixivaptan; Tolvaptan

Indexed keywords

CONIVAPTAN; LIXIVAPTAN; NEUROHORMONE; PLACEBO; TOLVAPTAN;

CARDIAC PATIENT; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DEATH; DRUG EFFECT; DYSPNEA; ELECTROLYTE DISTURBANCE; FOOT EDEMA; HEART FAILURE; HEART INDEX; HEART LEFT VENTRICLE; HEMODYNAMICS; HOSPITAL READMISSION; HUMAN; HYPONATREMIA; INTERNET; LONG TERM CARE; MEAN ARTERIAL PRESSURE; MEDLINE; OUTCOME ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; PULMONARY ARTERY OCCLUSION PRESSURE; REVIEW; SHORT COURSE THERAPY; SYSTOLIC BLOOD PRESSURE; URINE VOLUME; VASCULAR RESISTANCE;

AZEPINES; BENZAMIDES; BENZAZEPINES; HEART FAILURE; HUMANS; HYPONATREMIA; NEUROTRANSMITTER AGENTS; VASOPRESSINS;

EID: 77950611792     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1M660     Document Type: Review

References (19)

1. Hawkins RC. Age and gender as risk factors for hyponatremia and Hypernatremia. Clin Chim Acta 2003;337:169-172 (Pubitemid 37329815)
2. Verbalis JG, Goldsmith SR, Greenberg A, Schrier RW, Sterns RH. Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med 2007;120(11A):S1-S21. DOI 10.1016/j.amjmed.2007.09.001 (Pubitemid 350027722)
3. Gheorghiade M, Abraham WT, Albert NM, et al. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. Eur Heart J 2007;28:980-988 (Pubitemid 47343897)
4. Gheorgiade M, Rossi JS, Cotts W, et al. Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE trial. Arch Intern Med 2007;167:1998-2005. (Pubitemid 47606641)
5. Jessup M, Abraham WT, Casey DE, et al. 2009 Focused update: ACC/AHA guidelines for the diagnosis and management of heart failure in adults. Circulation 2009;119:1977-2016. DOI 10.1161/CIRCULATIONAHA.109.192064
6. Parker RB, Rodgers JE, Cavallari LH. Heart failure. In: DiPiro JT, Talbert RL, Yee GC, Matzke G, Wells B, Posey LM, eds. Pharmacotherapy: a pathophysiologic approach. 7th ed. New York, NY: McGraw Hill Medical, 2008:73-216.
7. Jackson EK. Vasopressin and other agents affecting the renal conservation of water. In: Burnton LL, LazoJS, Parker KL, eds. Goodman & Gilman's the pharmacological basis of therapeutics. 11th ed. New York, NY: McGraw Hill Medical, 2006:771-788
8. Package insert. Vaprisol (conivaptan). Deerfield, IL: Astellas Pharma US, October 2008.
9. Package insert. Samsca (tolvaptan). Rockville, MD: Otsuka America Pharmaceutical, Inc., May 2009.
10. Cardiokine, Inc. homepage. Status of lixivaptan development. http://www.cardiokine.com/HowLixivaptanWorks.htm (accessed 2009 Oct 30).
11. Udelson JE, Smith WB, Hendrix GH, et al. Acute hemodynamic effects of conivaptan, a dual V1A and V2 vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 2001;104:2417-2423 DOI 10.1161/hc4501.099313 (Pubitemid 33108374)
12. Goldsmith SR, Elkayam U, Haught WH, Barve A, He W. Efficacy and safety of the vasopressin V1A/V2-receptor antagonist conivaptan in acute decompensated heart failure: a dose-ranging pilot study. J Cardiac Fail 2008;14:641-647 DOI 10.1016/j.cardfail.2008.06.003
13. Udelson JE, Orlandi C, Ouyang J, et al. Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction. J Am Coll Cardiol 2008; 52:1540-1545 DOI 10.1016/j.jacc.2008.08.013
14. Gheorghiade M, Gattis WA, O'Connor CM, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure. JAMA 2004;291:1963-1971
15. Gheorghiade M, Konstam MA, Burnett JC, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure. JAMA 2007;297:1332-1343 DOI 10.001/jama.297.12.1332 (Pubitemid 46513233)
16. Abraham WT, Shamshirsaz AA, McFann K, Oren RM, Schrier RW. Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients. J Am Coll Cardiol 2006;47:1615-1621 DOI 10.1016/j.jacc.2005.11.071
17. Udelson JE, McGrew FA, Flores E, et al. Multicenter, randomized, doubleblind placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. J Am Coll Cardiol 2007;49:2151-2159 DOI 10.1016/j.jacc.2007.01.091 (Pubitemid 46817812)
18. Konstam MA, Gheorghiade M, Burnett JC, et al. Effects of tolvaptan in patients hospitalized for worsening heart failure. JAMA 2007;297:1319-1331 DOI 10.1001/jama.297.12.1319 (Pubitemid 46513233)
19. Green CP, Porter CB, Bresnahan DR, Spertus JA. Development and evaluation of the Kansas City cardiomyopathy questionnaire: a new health status measure for heart failure. J Am Coll Cardiol 2000;35:1245-1255